# Philip Morris Products S.A. clinical trials: 49 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 49 trials with Philip Morris Products S.A. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Philip Morris Products S.A.: 49 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/philip-morris-products-s-a

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 49
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 49, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 10, 2026 | NCT07459712 | Pharmacokinetics and Pharmacodynamics of THS With LEVIA Compared to THS With TEREA and to Cigarettes | Philip Morris Products S.A. | Not applicable | Completed | Nicotine | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07459712) |
| March 2, 2026 | NCT07443631 | Assessment of HPHC Exposure in Smokers Switching to THS/TP18 With Different Device Variants | Philip Morris Products S.A. | Not applicable | Active not recruiting | Smoking | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07443631) |
| February 13, 2026 | NCT07408180 | Exploratory Randomized, Controlled, Dose-response Study on the Impact of Nicotine From Five Variants of a Nicotine Tablet (NICOTINE TABLET)... | Philip Morris Products S.A. | Not applicable | Completed | Attention | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07408180) |
| August 22, 2025 | NCT07135648 | Nicotine Pharmacokinetics and Pharmacodynamics of Two Variants of VM 1.0 Compared to Cigarettes in Adult Current Smokers | Philip Morris Products S.A. | Not applicable | Active not recruiting | Nicotine | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07135648) |
| August 6, 2025 | NCT07108166 | Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS | Philip Morris Products S.A. | Not applicable | Active not recruiting | COPD, Smoking, Tobacco Use | 290 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07108166) |
| December 14, 2023 | NCT06171490 | Pharmacokinetics and Comparative Bioavailability of Nicotine From Two Variants of NP2, NP2-4mg and NP2-6mg, Compared to Nicotine Lozenge... | Philip Morris Products S.A. | Not applicable | Completed | Tobacco Use | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06171490) |
| March 29, 2023 | NCT05789420 | Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG | Philip Morris Products S.A. | Not applicable | Completed | Smoking, Tobacco | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05789420) |
| October 31, 2022 | NCT05599451 | Reduced Exposure to HPHC in Smokers Switching From Cigarettes to Different Versions of THS | Philip Morris Products S.A. | Not applicable | Completed | Smoking, Tobacco Smoking, Tobacco Use | 91 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05599451) |
| October 6, 2022 | NCT05569005 | Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms. | Philip Morris Products S.A. | Not applicable | Terminated | COPD, Smoking, Tobacco Use | 715 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05569005) |
| October 4, 2022 | NCT05566678 | Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic Disease | Philip Morris Products S.A. | Not applicable | Withdrawn | Cardiovascular Diseases, Smoking, Tobacco Use, Peripheral Arterial Disease, Coronary Artery Disease | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05566678) |
| August 4, 2022 | NCT05487456 | Reduced HPHC Exposure in Cigarette Smokers Switching to P4M3 Gen. 2.0 Compared to Continuing Smoking, or Smoking Abstinence | Philip Morris Products S.A. | Not applicable | Completed | Nicotine, Vaping, Nicotine Vaping | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05487456) |
| May 23, 2022 | NCT05385055 | Reduction of Exposure, Inflammation, and Oxidative Stress Following at Least 2 Years of Switching to THS Use Compared to Cigarette Smoking | Philip Morris Products S.A. | Observational | Completed | Inflammation, Oxidative Stress, Smoking, Smoking Abstinence | 974 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05385055) |
| May 20, 2022 | NCT05383508 | Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes | Philip Morris Products S.A. | Not applicable | Completed | Nicotine Vaping, Nicotine, Vaping | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05383508) |
| April 7, 2022 | NCT05317195 | Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy... | Philip Morris Products S.A. | Not applicable | Completed | Smoking, Nicotine | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05317195) |
| May 16, 2019 | NCT03953183 | Product Use and Adaptation, Safety and Tolerability of P3P in Adult Healthy Smokers Switching to it | Philip Morris Products S.A. | Not applicable | Completed | Pharmacokinetics | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03953183) |
| March 22, 2019 | NCT03887117 | Effect of Switching From Cigarette Smoking to IQOS on Exercise Capacity | Philip Morris Products S.A. | Not applicable | Completed | Smoking, Exercise Capacity | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03887117) |
| February 12, 2019 | NCT03837704 | Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking. | Philip Morris Products S.A. | Not applicable | Completed | Smoking, Abdominal Aortic Aneurysm, IQOS Use | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03837704) |
| June 11, 2018 | NCT03550989 | Real-Life Passive Exposure Assessment of IQOS | Philip Morris Products S.A. | Observational | Completed | Environmental Exposure | 401 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03550989) |
| May 16, 2018 | NCT03527030 | Cross-Sectional Survey on the Use of Tobacco Products - London (UK) | Philip Morris Products S.A. | Observational | Terminated | Tobacco Use | 6,116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03527030) |
| May 16, 2018 | NCT03527017 | Cross-Sectional Survey on the Use of Tobacco Products - Germany | Philip Morris Products S.A. | Observational | Terminated | Tobacco Use | 6,284 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03527017) |
| May 16, 2018 | NCT03527004 | Cross-Sectional Survey on the Use of Tobacco Products - Italy | Philip Morris Products S.A. | Observational | Terminated | Tobacco Use | 6,107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03527004) |
| December 20, 2017 | NCT03379740 | Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of P4M3 Variants | Philip Morris Products S.A. | Not applicable | Completed | Vaping, Nicotine Absorption | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03379740) |
| December 12, 2017 | NCT03369340 | Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P | Philip Morris Products S.A. | Not applicable | Completed | Pharmacokinetics | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03369340) |
| December 7, 2017 | NCT03364751 | Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome | Philip Morris Products S.A. | Not applicable | Completed | Periodontal Diseases, Chronic Periodontitis, Periodontal Pocket, Tooth Mobility, Gingival Diseases, Smoking, Cigarette | 179 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03364751) |
| March 22, 2017 | NCT03086707 | Prefatory Study to Explore Changes in Nasal Mucociliary Clearance and to Standardize Nasal Scraping Procedure | Philip Morris Products S.A. | Not applicable | Completed | Smokers, Never Smokers | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03086707) |

## By phase

| Phase | Trials |
| --- | --- |
| Not applicable | 39 |
| Observational | 10 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 40 |
| Terminated | 5 |
| Active not recruiting | 3 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Smoking | 35 |
| Tobacco Use | 8 |
| Vaping | 4 |
| Cigarette Smoking | 3 |
| Pulmonary Disease, Chronic Obstructive | 3 |
| Tobacco Smoking | 2 |
| Smoking Cessation | 1 |
| Periodontal Diseases | 1 |
| Chronic Periodontitis | 1 |
| Periodontal Pocket | 1 |
| Tooth Mobility | 1 |
| Gingival Diseases | 1 |
| Aortic Aneurysm, Abdominal | 1 |
| Cardiovascular Diseases | 1 |
| Peripheral Arterial Disease | 1 |
| Coronary Artery Disease | 1 |
| Atherosclerosis | 1 |
| Inflammation | 1 |
| Pneumonia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Fmcg wholesalers in the United States](https://specstream.ai/data/businesses/fmcg-wholesalers/united-states)
- [Lodges in the United States](https://specstream.ai/data/businesses/lodges/united-states)
- [Promotional products companies in the United States](https://specstream.ai/data/businesses/promotional-products-companies/united-states)
- [Truck repair shops in the United States](https://specstream.ai/data/businesses/truck-repair-shops/united-states)
- [Bangladeshi restaurants in the United States](https://specstream.ai/data/businesses/bangladeshi-restaurants/united-states)
- [Document shredding companies in the United States](https://specstream.ai/data/businesses/document-shredding-companies/united-states)
